StockNews.com began coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently issued reports on XENE. Wedbush reiterated an outperform rating and set a $47.00 price objective […]